{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Bicycle Therapeutics plc"},"Symbol":{"label":"Symbol","value":"BCYC"},"Address":{"label":"Address","value":"B900, BABRAHAM RESEARCH CAMPUS BLOCKS A AND B, PORTWAY BUILDING, CAMBRIDGE, CB22 3AT, United Kingdom"},"Phone":{"label":"Phone","value":"+44 1223261503"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need."},"CompanyUrl":{"label":"Company Url","value":"https://www.bicycletherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alistair Milnes","title":"Chief Operating Officer"},{"name":"Kevin Lee","title":"Chief Executive Officer & Executive Director"},{"name":"Michael Skynner","title":"Chief Technology Officer"},{"name":"Nicholas Keen","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}